<DOC>
	<DOCNO>NCT02217943</DOCNO>
	<brief_summary>The primary goal study assess impact metabolic surgery glycemic control diabetic patient .</brief_summary>
	<brief_title>Prospective Metabolic Surgery T2DM Chinese Subjects</brief_title>
	<detailed_description>The primary objective study assess impact metabolic surgery ( Roux-en-Y gastric bypass [ RYGB ] sleeve gastrectomy [ SG ] ) composite measure glycemic control 2 year post surgery Type 2 Diabetes Mellitus ( T2DM ) cohort subject .</detailed_description>
	<criteria>1 . 20 60 year age ( inclusive ) date inform consent document ( ICD ) sign ; 2 . A body mass index ( BMI ) 28 kg/m2 50 kg/m2 ; 3 . Previously diagnose least 6 month T2DM accord World Health Organization ( WHO ) criteria ; 4 . Cpeptide &gt; 1 ng/mL ( 0.3 nmol/L ) ; 5 . Able willing comply procedure require protocol ; 6 . Able comprehend sign , illiterate , leave thumb impression study ICD . 1 . History T2DM duration &gt; 10 year ; 2 . History drug and/or alcohol abuse within 2 year Screening Visit ; 3 . Any previous major GI surgery ( e.g. , GI surgery resection , etc. ) . Previous GI surgery allow include : appendectomy , gall bladder surgery , liver biopsy , endoscopic procedure ; 4 . Scheduled concurrent surgical , nonendoscopy , procedure Visit 1 end Visit 3 ; 5 . Women childbearing potential pregnant lactating time screen , time surgery , plan become pregnant one year sooner surgery ; 6 . Psychiatric disorder may affect compliance clinical study , include dementia , active psychosis , severe depression , history suicide attempt ; 7 . Any following condition : 1 . Inflammatory disease GI tract , include severe intractable esophagitis , gastric ulceration , duodenal ulceration , specific inflammation Crohn 's disease ulcerative colitis active within past 10 year ; 2 . End stage renal disease ; 3 . Abnormal result glutamic acid decarboxylase autoantibody ( GADA ) protein tyrosine phosphataselike protein ( IA2A ) testing ; 4 . Immunocompromised result chronic oral steroid use , cancer chemotherapeutic agent , immune deficiency disorder ; 8 . Participation clinical study ( include registry surveyonly study ) within 30days 5 halflives investigational drug ( ever longer ) , Visit 1 ( Screening Visit ) duration study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>